Anti-COVID-19 Compound Library
Cat. No. : | CS-L052 | (1477 compounds) |
---|
COVID-19 poses a serious threat to people's health, and it is urgent to develop drugs to treat COVID-19 quickly. The screening of anti-COVID-19 drugs by using the clinical and approved compounds can greatly shorten the research and development cycle. In addition, the virtual screening technology can effectively narrow the scope of screening and improve the screening efficiency in the pre-screening of new drugs.
Taking advantage of our virtual screening, we conduct virtual screening of approved compound library and clinical compound library based on the 3CL protease (PDB ID: 6LU7), Spike Glycoprotein (PDB ID: 6VSB), NSP15 (PDB ID: 6VWW), RDRP, PLPro and ACE2 (Angiotensin Converting Enzyme 2) structure. We design a unique collection of 1477 compounds which may have anti-COVID-19 activity. Anti-COVID-19 Compound Library will be a powerful tool for screening new anti-COVID-19 activity drugs.
Size (Pre-dissolved DMSO or Solid) | Stock | Price |
---|---|---|
30 μL/well (10 mM solution) | In-stock | Get quote |
50 μL/well (10 mM solution) | In-stock | Get quote |
100 μL/well (10 mM solution) | In-stock | Get quote |
250 μL/well (10 mM solution) | In-stock | Get quote |
Data Sheet
Description & Advantages
Composition
Contents
Formulation: | A collection of 1477 compounds that may have anti-COVID-19 activity supplied as pre-dissolved Solutions or Solid |
---|---|
Container: | 96- or 384-well Plate with Peelable Foil Seal; 96-well Format Sample Storage Tube With Screw Cap and Optional 2D Barcode |
Storage: | -80°C |
Shipping: | Blue ice |
Customize Your Library
You can select:- Specific Compounds
- Quantities
- Plate map
- Concentration
- Format (Solid or DMSO Solution)
Please contact us at sales@chemscene.com